A Novel Glucocerebrosidase Allosteric Activator Prevents MPTP-Induced Neurodegeneration in Mice

Mutations in the GBA1 gene, encoding lysosomal β-glucocerebrosidase (GCase), cause Gaucher disease (GD) and represent the most common genetic risk factor for Parkinson’s disease (PD). To target this pathway, therapeutic approaches for both GD and PD are actively being developed, focusing on two main drug classes: pharmacological chaperones (e.g., ambroxol) and allosteric GCase activators. Here, we characterize a novel allosteric GCase activator, N2, a derivative of the non-inhibitory chaperone NCGC607, and evaluate its therapeutic potential using computational, in vitro, and in vivo approaches. Molecular docking and molecular dynamics simulations indicated that N2 binds within the allosteric site of the mutant p.N370S GCase structure. In patient-derived cells (peripheral blood mononuclear cell-derived macrophages and induced pluripotent stem cell-derived dopaminergic neurons from GD and GBA1-PD patients), N2 enhanced GCase lysosomal translocation, modulated its enzymatic activity and protein level, and reduced substrate accumulation. Furthermore, we demonstrate for the first time that N2 exerts robust neuroprotective effects in an in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD. Specifically, N2 treatment attenuated MPTP-induced hexosylsphingosine accumulation in the prefrontal cortex, and ameliorated both tyrosine hydroxylase-positive neuronal loss in the substantia nigra and dopamine depletion in the striatum. Our findings first demonstrated the neuroprotective properties of a GCase allosteric activator on an MPTP-induced mouse model of PD and supported the emerging perspectives of such compounds for the treatment of GCase-related disorders.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-10-27
DOI
https://doi.org/10.3390/ijms27219602
Primary Topic
Lysosomal Storage Disorders Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Novel Glucocerebrosidase Allosteric Activator Prevents MPTP-Induced Neurodegeneration in Mice

Mikhail A. Nikolaev, Petr A. Slominsky, Ekaterina Zakharova, Е. И. Семенова et al.
2 links
International Journal of Molecular Sciences
Lysosomal Storage Disorders Research
article

A Novel Glucocerebrosidase Allosteric Activator Prevents MPTP-Induced Neurodegeneration in Mice

Mikhail A. Nikolaev, Petr A. Slominsky, Ekaterina Zakharova, Е. И. Семенова, С. Н. Пчелина, Tatiana S. Usenko, Elena V. Grigor’eva, V. V. Kvanchiani, Vadim A. Bezrukikh, Alexander V. Stepakov, Sophia V. Pavlova, Alena E. Kopytova, Irina V. Miliukhina, Georgy N. Rychkov, Vitali M. Boitsov, Maria Shadrina, Лавринова Анна Олеговна, Galina Baydakova, Suzanna A. Partevian, Т. Н. Федорова, Alla Timofeeva, Alexandra V. Artynyuk, Victoria N. Pidyurchina, Farid Ibatullin, Ivan Rybolovlev, Anton Emelyanov, Ekaterina Sergeeva, Margarita Rudenok, Anastasia Bezrukova, Maxim Nesterov
article en

Abstract

Mutations in the GBA1 gene, encoding lysosomal β-glucocerebrosidase (GCase), cause Gaucher disease (GD) and represent the most common genetic risk factor for Parkinson’s disease (PD). To target this pathway, therapeutic approaches for both GD and PD are actively being developed, focusing on two main drug classes: pharmacological chaperones (e.g., ambroxol) and allosteric GCase activators. Here, we characterize a novel allosteric GCase activator, N2, a derivative of the non-inhibitory chaperone NCGC607, and evaluate its therapeutic potential using computational, in vitro, and in vivo approaches. Molecular docking and molecular dynamics simulations indicated that N2 binds within the allosteric site of the mutant p.N370S GCase structure. In patient-derived cells (peripheral blood mononuclear cell-derived macrophages and induced pluripotent stem cell-derived dopaminergic neurons from GD and GBA1-PD patients), N2 enhanced GCase lysosomal translocation, modulated its enzymatic activity and protein level, and reduced substrate accumulation. Furthermore, we demonstrate for the first time that N2 exerts robust neuroprotective effects in an in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD. Specifically, N2 treatment attenuated MPTP-induced hexosylsphingosine accumulation in the prefrontal cortex, and ameliorated both tyrosine hydroxylase-positive neuronal loss in the substantia nigra and dopamine depletion in the striatum. Our findings first demonstrated the neuroprotective properties of a GCase allosteric activator on an MPTP-induced mouse model of PD and supported the emerging perspectives of such compounds for the treatment of GCase-related disorders.

International Journal of Molecular SciencesVol. 27(21)
Peter the Great St. Petersburg Polytechnic University (RU), First Pavlov State Medical University of St. Petersburg (RU), Kurchatov Institute (RU), Federal Almazov North-West Medical Research Centre (RU), Institute of the Human Brain (RU), Institute of Cytology and Genetics (RU), Research Centre for Medical Genetics (RU), Petersburg Nuclear Physics Institute (RU), Research Center of Neurology (RU), Federal Medical-Biological Agency (RU), St. Petersburg State Technological Institute (RU)
Russian Science Foundation
Good health and well-being
Openalex Percentile: Top 13%
Lysosomal Storage Disorders Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon